Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412

C M Dayan1, D C Wraith

  • 1Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Dorothy Hodgkin Building, University of Bristol, Bristol, UK. colin.dayan@bris.ac.uk

Current immunology research is generating many new approaches to immunotherapy. However, the recent disaster surrounding the testing of TGN1412, has unsettled regulators and the pharmaceutical industry regarding new immunotherapies and highlighted the complexities of conducting clinical trials with agents that target the immune system. Here we discuss the critical role for immunologists in ensuring that the development of new immunotherapies continues.

Related Concept Videos